BioCentury | Nov 3, 2008
Company News

MuriGen, CSL deal

...antibodies that inhibit G-CSF or its receptor to treat arthritis and inflammatory diseases. In return, MuriGen...
...between MuriGen and Zenyth Therapeutics Ltd. (now part of CSL) (see BioCentury, Feb. 26, 2006). MuriGen Therapeutics...
BioCentury | Jul 24, 2006
Company News

CSL, Zenyth deal

...with Cambridge Antibody Technology Group plc (LSE:CAT; CATG, Cambridge, U.K.) and the G-CSF product with MuriGen...
BioCentury | Jul 18, 2006
Company News

CSL to acquire Zenyth

...is codeveloping the GM-CSFR product with Cambridge Antibody (LSE:CAT; CATG) and the G-CSF product with MuriGen...
BioCentury | Feb 27, 2006
Company News

MuriGen Pty Ltd, Zenyth deal

...to treat arthritis and other inflammatory diseases. The deal combines ZTL's antibody generation capabilities with MuriGen's...
...Dyax Corp. (DYAX, Cambridge, Mass.). ZTL and MuriGen will jointly fund R&D through clinical proof-of-concept. MuriGen...
BioCentury | Feb 22, 2006
Company News

Zenyth, MuriGen antibody deal

...Zenyth (ASX:ZTL) and MuriGen (Victoria, Australia) will research and develop therapeutic proteins that inhibit G-CSF or...
...to treat arthritis and other inflammatory diseases. The deal combines ZTL's antibody generation capabilities with MuriGen's...
...ZTL also said it will use phage display antibody libraries from Dyax (DYAX). ZTL and MuriGen...
Items per page:
1 - 5 of 5
BioCentury | Nov 3, 2008
Company News

MuriGen, CSL deal

...antibodies that inhibit G-CSF or its receptor to treat arthritis and inflammatory diseases. In return, MuriGen...
...between MuriGen and Zenyth Therapeutics Ltd. (now part of CSL) (see BioCentury, Feb. 26, 2006). MuriGen Therapeutics...
BioCentury | Jul 24, 2006
Company News

CSL, Zenyth deal

...with Cambridge Antibody Technology Group plc (LSE:CAT; CATG, Cambridge, U.K.) and the G-CSF product with MuriGen...
BioCentury | Jul 18, 2006
Company News

CSL to acquire Zenyth

...is codeveloping the GM-CSFR product with Cambridge Antibody (LSE:CAT; CATG) and the G-CSF product with MuriGen...
BioCentury | Feb 27, 2006
Company News

MuriGen Pty Ltd, Zenyth deal

...to treat arthritis and other inflammatory diseases. The deal combines ZTL's antibody generation capabilities with MuriGen's...
...Dyax Corp. (DYAX, Cambridge, Mass.). ZTL and MuriGen will jointly fund R&D through clinical proof-of-concept. MuriGen...
BioCentury | Feb 22, 2006
Company News

Zenyth, MuriGen antibody deal

...Zenyth (ASX:ZTL) and MuriGen (Victoria, Australia) will research and develop therapeutic proteins that inhibit G-CSF or...
...to treat arthritis and other inflammatory diseases. The deal combines ZTL's antibody generation capabilities with MuriGen's...
...ZTL also said it will use phage display antibody libraries from Dyax (DYAX). ZTL and MuriGen...
Items per page:
1 - 5 of 5